Vitamin D levels in Swiss breast cancer survivors.

Autor:	Baumann M; Institute for Clinical Chemistry and Haematology, St Gallen Cantonal Hospital, Switzerland., Dani SU; Department of Medical Oncology and Haematology, St Gallen Cantonal Hospital, Switzerland., Dietrich D; Statistical Office, Swiss Group for Clinical Cancer Research Coordinating Centre - SAKK, Bern, Switzerland., Hochstrasser A; Oncology Centre, Männedorf Hospital, Zurich, Switzerland., Klingbiel D; Statistical Office, Swiss Group for Clinical Cancer Research Coordinating Centre - SAKK, Bern, Switzerland., Mark MT; Department of Oncology and Haematology, Graubuenden Cantonal Hospital, Chur, Switzerland., Riesen WF; Institute for Clinical Chemistry and Haematology, St Gallen Cantonal Hospital, Switzerland., Ruhstaller T; Breast Centre St Gallen, St Gallen Cantonal Hospital, Switzerland., Templeton AJ; Department of Oncology, St Claraspital Basel and Faculty of Medicine, University of Basel, Switzerland., Thürlimann B; Breast Centre St Gallen, St Gallen Cantonal Hospital, Switzerland.
Jazyk:	angličtina
Zdroj:	Swiss medical weekly [Swiss Med Wkly] 2018 Jan 16; Vol. 148, pp. w14576. Date of Electronic Publication: 2018 Jan 16 (Print Publication: 2018).
DOI:	10.4414/smw.2018.14576
Abstrakt:	Background: Cholecalciferol (vitamin D3) is widely supplemented in breast cancer survivors because of the role of vitamin D in multiple health outcomes. Methods: We conducted an observational study in 332 women in Eastern Switzerland with early, i.e., nonmetastatic breast cancer. Tumour-, patient-related and sociodemographic variables were recorded. Cholecalciferol intake and serum 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were measured at the first visit (baseline) and during a follow-up visit in a median of 210 days (range 87-857) after the first visit. Patients presenting 25(OH)D deficiency were advised to take cholecalciferol supplementation. Results: At baseline, 60 (18%) patients had 25(OH)D deficiency (≤50 nmol/l, ≤20 ng/l), and 70 (21%) had insufficiency (50-74 nmol/l, 20-29 ng/l). Out of 121 patients with ongoing cholecalciferol supplementation at baseline, 25(OH)D deficiency and insufficiency was observed in 9 (7%) and 16 (13%) patients, respectively, whereas out of 52 patients with no supplementation, 15 (29%) had deficiency and 19 (37%) had insufficiency. Only 85 (26%) patients had optimal 25(OH)D levels (75-100 nmol/l, 30-40 ng/l) at baseline. Seasonal variation was significant for 25(OH)D (p = 0.042) and 1,25(OH)2D (p = 0.001) levels. Living in a rural area was associated with a higher median 25(OH)D concentration as compared with living in an urban area (87 nmol/l, range 16-216 vs 72 nmol/l, range 17-162; p = 0.001). Regular sporting activity was positively associated with 25(OH)D (p = 0.045). Body mass index was inversely related to both 25(OH)D and 1,25(OH)2D (Spearman's rho = -0.24, p <0.001; rho = -0.23, p <0.001, respectively). The levels of 25(OH)D and 1,25(OH)2D were correlated (rho = 0.21, p <0.001). Age and bone mineral density had no significant correlation with the levels of 25(OH)D. Follow-up 25(OH)D was available for 230 patients, 44 (19%) of whom had 25(OH)D deficiency and 47 (21%) had insufficiency; 25 (41.6%) initially 25(OH)D-deficient patients attained sufficient 25(OH)D levels, whereas 33 (16.5%) patients with sufficient baseline 25(OH)D levels became deficient. Only 67 (30%) patients presented optimal 25(OH)D at the follow-up. Conclusion: A remarkable fraction of the patients had serum 25(OH)D below (40%) or above (30%) optimal levels, and only around 30% of patients had optimal levels. Levels of 25(OH)D and 1,25(OH)2D increased on cholecalciferol supplementation, but the usual supplementation regimens were not adequate to bring 25(OH)D to the optimal range for a large proportion of patients. Trial Registration Number: EKSG 08/082/2B.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu